"As the Company expands its clinical study sites in the US and Europe and responds to requests for access to Veyonda, it has focused on scaling up its manufacturing pipeline to supply this surge in demand."
NOX should be enquiring about schemes such as the TGA's special access scheme. Here is a link https://www.tga.gov.au/form/special-access-scheme
That way NOX can not only provide the treatment, but also get reimbursed for doing so, while collecting data at the same time. It may not seem like much but its still revenue and cash in the bank.
"As the Company expands its clinical study sites in the US and...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
